It has been known for decades that there is a co-morbidity of depression in epilepsy and recently, depression has been identified as a risk factor for epilepsy, highlighting the overlap in the pathophysiology of these diseases. However, very few studies have addressed the mechanisms mediating the co-morbidity of depression and epilepsy. Stress is a trigger for both of these disorders, and we hypothesize that dysfunction in the body's stress response, mediated by the hypothalamic-pituitary-adrenal (HPA) axis, and may play a role in the co-morbidity of depression and epilepsy. A hallmark characteristic of depression is hyperexcitability of the HPA axis and seizure activity activates the HPA axis. The output of the HPA axis is mediated by corticotrophin-releasing hormone (CRH) neurons in the paraventricular nucleus (PVN), the activity of which are under robust GABAergic control. This proposal will test the hypothesis that dysfunction in GABAergic control of the HPA axis results in hyperexcitability of the HPA axis, leading to increased seizure susceptibility. We have developed a sophisticated set of tools to test this hypothesis, including a novel, conditional knockout of one of the principal GABAARs regulating the HPA axis, the Gabrd gene. We intend to cross these mice with CRH-Cre mice to generate mice with GABAergic deficits specifically in the CRH neurons regulating the output of the HPA axis. Further, we will investigate whether an initial seizure insult alters GABAAR subunit expression in the PVN, as it does in other brain regions, thereby leading to HPA axis hyperexcitability and future seizures. Insight into the role of GABAergic control of the HPA axis in the co-morbidity of epilepsy and depression may identify novel therapeutic targets for both epilepsy and depression as well as the co-morbidity of the two, which complements the mission of the NINDS to reduce the burden of neurological diseases through research and the new strategic plan to identify new potential therapies for neurological diseases.
Insight into mechanisms underlying the significant co-morbidity of epilepsy and depression will have therapeutic potential for both of these disorders as well as the co-morbidity of the two. The body's stress response, which is under the control of the major inhibitory neurotransmitter, GABA, has been implicated in the pathophysiology of these two diseases separately and we hypothesize may be involved in the co-morbidity. We have developed a unique mouse model, which is deficient in the GABAergic regulation of the stress response, to investigate the impact on the co-morbidity of depression and epilepsy.
|Melón, Laverne; Hammond, Rebecca; Lewis, Mike et al. (2018) A Novel, Synthetic, Neuroactive Steroid Is Effective at Decreasing Depression-Like Behaviors and Improving Maternal Care in Preclinical Models of Postpartum Depression. Front Endocrinol (Lausanne) 9:703|
|Melón, Laverne Camille; Hooper, Andrew; Yang, Xuzhong et al. (2018) Inability to suppress the stress-induced activation of the HPA axis during the peripartum period engenders deficits in postpartum behaviors in mice. Psychoneuroendocrinology 90:182-193|
|Molaie, Amir M; Maguire, Jamie (2018) Neuroendocrine Abnormalities Following Traumatic Brain Injury: An Important Contributor to Neuropsychiatric Sequelae. Front Endocrinol (Lausanne) 9:176|
|Hooper, Andrew; Paracha, Rumzah; Maguire, Jamie (2018) Seizure-induced activation of the HPA axis increases seizure frequency and comorbid depression-like behaviors. Epilepsy Behav 78:124-133|
|Fuchs, T; Jefferson, S J; Hooper, A et al. (2017) Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state. Mol Psychiatry 22:920-930|
|Mukherjee, Jayanta; Cardarelli, Ross A; Cantaut-Belarif, Yasmine et al. (2017) Estradiol modulates the efficacy of synaptic inhibition by decreasing the dwell time of GABAA receptors at inhibitory synapses. Proc Natl Acad Sci U S A 114:11763-11768|
|Fuchs, T; Jefferson, S J; Hooper, A et al. (2017) Disinhibition of somatostatin-positive interneurons by deletion of postsynaptic GABAA receptors. Mol Psychiatry 22:787|
|Sivakumaran, Sudhir; Maguire, Jamie (2016) Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus. Epilepsia 57:222-32|
|Maguire, Jamie (2016) Neurosteroid Deficiency Associated With Epilepsy. Epilepsy Curr 16:108-9|
|Maguire, Jamie (2016) Epileptogenesis: More Than Just the Latent Period. Epilepsy Curr 16:31-3|
Showing the most recent 10 out of 37 publications